Skip to main content
    L

    Lantern Pharma Inc (LTRN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.39
    -0.04 (-10.18%)

    Market Cap: $6.47M

    Last updated: Nov 17, 2026 at 11:01 AM ET

    Lantern Pharma Inc (LTRN) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Lantern Pharma (LTRN) to earn -$1.51 per share in the fiscal year ending Dec 31, 2026. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$2.02.

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss.

    Fiscal year ending Dec 31, 2026
    -$1.51
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$2.02
    EPS consensus
    Next report
    Nov 17, 2026
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$1.51-$1.51 to -$1.511
    Dec 31, 2027-$2.02-$2.02 to -$2.021

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.42N/A3

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 1 upward and 0 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202700

    EPS Trend

    The EPS consensus for the fiscal year ending Dec 31, 2026 has held over the last 90 days.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$1.51-$1.51-$1.51-$1.51-$1.51N/A
    Fiscal year ending Dec 31, 2027-$2.02-$2.02-$2.02-$2.02-$2.02N/A

    Frequently Asked Questions About LTRN

    What is the LTRN stock forecast?

    Consensus analyst estimates put Lantern Pharma's EPS at -$1.51 for the fiscal year ending Dec 31, 2026.

    What EPS do analysts expect from LTRN next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.51, with estimates from -$1.51 to -$1.51 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.02, with estimates from -$2.02 to -$2.02 from 1 analyst.

    How many analysts cover LTRN?

    1 analyst estimates EPS for Lantern Pharma for the fiscal year ending Dec 31, 2026.